La Roche Posay Laboratoire Dermatologique Effaclar Duo Plus M Multi Target Ac...

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the treatment of acne vulgaris. It effectively clears existing acne blemishes and penetrates pores to control the formation of acne lesions. Additionally, this drug helps prevent the emergence of new acne blemishes, contributing to overall skin health and clarity.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleaned prior to the application of this product. A thin layer should be applied to the entire affected area one to three times daily, depending on the patient's needs and the physician's recommendations.

It is advisable to initiate treatment with one application per day to minimize the risk of excessive skin drying. The frequency may be gradually increased to two or three times daily as tolerated. Should the patient experience bothersome dryness or peeling, the application frequency should be reduced to once daily or every other day.

For patients who will be exposed to sunlight, it is important to apply sunscreen after using this product. In cases where irritation or sensitivity occurs, the use of both the product and sunscreen should be discontinued, and the patient should consult a physician for further guidance.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

For external use only. It is imperative that this product is not ingested. In the event of accidental swallowing, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Healthcare professionals should advise patients to discontinue use and consult their physician if any irritation develops. It is recommended that patients utilize only one topical acne medication concurrently to minimize the risk of adverse reactions.

Side Effects

For external use only. No specific side effects or adverse reactions have been reported in clinical trials or postmarketing experiences. Patients should be advised to use the product as directed and to consult a healthcare professional if any unexpected reactions occur.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to alleviate symptoms. Monitoring for signs of skin irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of La Roche Posay Laboratoire Dermatologique Effaclar Duo Plus M Multi Target Acne Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily. Depending on the patient's response and as directed by a healthcare professional, the frequency may be gradually increased to two or three times daily. Care should be taken to observe for signs of excessive drying of the skin; if bothersome dryness or peeling occurs, the application frequency should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There are no specific warnings or precautions regarding the use of this product during pregnancy. The prescribing information does not indicate whether the product is contraindicated in pregnancy or if there are any risks to the fetus associated with its use. Additionally, no dosage modifications or special precautions for pregnant individuals are provided. Healthcare professionals should consider the absence of data when advising pregnant patients and weigh the potential benefits against any unknown risks.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider general principles of management for potential overdose situations.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

Additionally, contacting a poison control center or a medical toxicologist for guidance on specific management strategies is advisable. This approach ensures that appropriate measures are taken based on the clinical presentation and the substance involved.

Overall, vigilance and prompt action are critical in managing any potential overdosage scenarios effectively.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Additionally, healthcare providers should inform patients about the likelihood of skin irritation and dryness when using this medication concurrently with other topical acne treatments. Patients should be counseled to use only one topical acne medication at a time to minimize the risk of irritation. This guidance will help ensure safe and effective use of the medication while reducing the potential for adverse skin reactions.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) and protected from light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically. Clinicians should advise patients to apply sunscreen after using the product if they plan to go outside. In the event of irritation or sensitivity, patients are instructed to discontinue use of both the product and any other potentially irritating products, and to consult a doctor.

Drug Information (PDF)

This file contains official product information for La Roche Posay Laboratoire Dermatologique Effaclar Duo Plus M Multi Target Acne Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)